Preventing stroke in AF: New data on role of antithrombotic therapy

All forms of atrial fibrillation (AF), whether permanent, persistent, or paroxysmal, are associated with an increased risk of stroke and antithrombotic therapy is recommended for almost all AF patients.¹ Current guidelines are likely to evolve in response to studies that have appeared in the past year. This Data Alert reviews these studies as well as ongoing studies that also may influence clinical practice.

References are listed at the end of the Data Alert.

High incidence of asymptomatic AF

Download DA%20antithrombotic%20therapy.ppt (6 slides - 0.1MB)

High incidence of asymptomatic AF: Clinical implications

Warfarin increases hemorrhagic stroke mortality

Trials of emerging antithrombotic therapiesfor stroke prevention in AF

SPORTIF III and V pooled results:
Primary outcome

SPORTIF III and V pooled results:
Net clinical benefit

Data_Alert.pdf (0.5MB)

antithrombotic forms paroxysmal permanent Stroke

Related at vwbg.org

Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

View/Download individual slides (13 Slides)

Results from CRUSADE: Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines

CRUSADE investigated the association between dosing levels of antithrombotic agents and bleeding, in-hospital mortality, and length of stay in patients with NSTE ACS.

Expanding opportunities for secondary prevention of stroke

Between 1979 and 2001, the number of patients discharged from the hospital with a primary diagnosis of stroke increased by 25%.

More related